ARMC
REGN icon

American Research & Management Company’s Regeneron Pharmaceuticals REGN Stock Holding History

American Research & Management Company’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5
Closed -$2K – 385
2020
Q4 		$2K Hold
5
– – ﹤0.01% 356
2020
Q3 		$3K Hold
5
– – ﹤0.01% 322
2020
Q2 		$3K Buy
+5
New +$2.84K ﹤0.01% 320

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Research & Management Company's REGN Position: Q1 2021 in Review

American Research & Management Company sold out of Regeneron Pharmaceuticals (REGN) in Q1 2021, closing a stake of 5 shares — an estimated $2K sold.

American Research & Management Company first reported a position in REGN in Q2 2020 and held it in 3 quarters. The position peaked at $3K in Q3 2020. 924 funds tracked by Wall St. Rank hold REGN as of Q1 2021.

  • American Research & Management Company reported no remaining Regeneron Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • American Research & Management Company sold 5 Regeneron Pharmaceuticals shares in Q1 2021, an estimated $2K.
  • American Research & Management Company first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 3 quarters.
  • American Research & Management Company's Regeneron Pharmaceuticals position peaked at $3K in Q3 2020.
  • 924 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2021.

Based on American Research & Management Company's 13F filing for Q1 2021, filed 6 Apr 2021.